Join Growin Stock Community!

Cerus corporationCERS.US Overview

US StockHealthcare
(No presentation for CERS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CERS AI Insights

CERS Overall Performance

CERS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CERS Recent Performance

-20.17%

Cerus corporation

-3.61%

Avg of Sector

-2.16%

S&P500

CERS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CERS Key Information

CERS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CERS Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Price of CERS

CERS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CERS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.08
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.47
PB Ratio
8.16
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
58.65%
Net Margin
-6.89%
Revenue Growth (YoY)
12.74%
Profit Growth (YoY)
10.41%
3-Year Revenue Growth
4.01%
3-Year Profit Growth
-2.22%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.08
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
2.47
PB Ratio
8.16
Price-to-FCF
-
Gross Margin
58.65%
Net Margin
-6.89%
Revenue Growth (YoY)
12.74%
Profit Growth (YoY)
10.41%
3-Year Revenue Growth
4.01%
3-Year Profit Growth
-2.22%
  • When is CERS's latest earnings report released?

    The most recent financial report for Cerus corporation (CERS) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CERS's short-term business performance and financial health. For the latest updates on CERS's earnings releases, visit this page regularly.

  • What is the operating profit of CERS?

    According to the latest financial report, Cerus corporation (CERS) reported an Operating Profit of -641K with an Operating Margin of -1.11% this period, representing a growth of 55.76% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is CERS's revenue growth?

    In the latest financial report, Cerus corporation (CERS) announced revenue of 57.75M, with a Year-Over-Year growth rate of 1.76%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does CERS have?

    As of the end of the reporting period, Cerus corporation (CERS) had total debt of 56.4M, with a debt ratio of 0.25. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does CERS have?

    At the end of the period, Cerus corporation (CERS) held Total Cash and Cash Equivalents of 19.96M, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does CERS go with three margins increasing?

    In the latest report, Cerus corporation (CERS) did not achieve the “three margins increasing” benchmark, with a gross margin of 51.51%%, operating margin of -1.11%%, and net margin of -3.78%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess CERS's profit trajectory and future growth potential.

  • Is CERS's EPS continuing to grow?

    According to the past four quarterly reports, Cerus corporation (CERS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.01. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CERS?

    Cerus corporation (CERS)'s Free Cash Flow (FCF) for the period is 94K, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 97.19% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CERS?

    The latest valuation data shows Cerus corporation (CERS) has a Price-To-Earnings (PE) ratio of -44.94 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.